down arrow

Lumos Pharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US55028X1090
USD
4.34
0.00 (0.00%)

Dec 13

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

3.444.58
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

0.37%

Held by 6 FIIs

DII

94.44%

Held by 4 DIIs

Promoter

0.97%

What does Lumos Pharma, Inc. do?

22-Jun-2025

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for rare diseases, with a market cap of $37.53 million and quarterly net sales of $1 million. As of September 2024, it reported a net loss of $7 million.

Overview: <BR>Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases, specifically in the Pharmaceuticals industry with a micro-cap market classification.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Million (Quarterly Results - Sep 2024) <BR>Net Profit: -7 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 37.53 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 8,985.11% <BR>Debt Equity: -1.50 <BR>Return on Equity: -710.54% <BR>Price to Book: 7.64<BR><BR>Contact Details: <BR>Address: 4200 MARATHON BLVD., SUITE 200, AUSTIN TX: 78756 <BR>Tel: 1 512 2152630 <BR>Fax: 1 515 2963520 <BR>Website: https://lumos-pharma.com/

Read More

Who are in the management team of Lumos Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Lumos Pharma, Inc. includes Richard Hawkins (Chairman, President, CEO), Dr. Thomas Raffin (Lead Independent Director), Dr. Nicholas Vahanian, Dr. Emmett Cunningham, Mr. Chad Johnson, and Mr. Kevin Lalande (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Lumos Pharma, Inc. includes the following individuals:<BR><BR>- Mr. Richard Hawkins: Chairman of the Board, President, Chief Executive Officer<BR>- Dr. Thomas Raffin: Lead Independent Director<BR>- Dr. Nicholas Vahanian: Director<BR>- Dr. Emmett Cunningham: Independent Director<BR>- Mr. Chad Johnson: Independent Director<BR>- Mr. Kevin Lalande: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Lumos Pharma, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data on Lumos Pharma, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for Lumos Pharma, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Lumos Pharma, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Lumos Pharma, Inc. is considered attractive due to its undervaluation, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%, making it cheaper than peers like Amgen and Vertex Pharmaceuticals while outperforming the Sensex.

As of 15 October 2023, Lumos Pharma, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%. <BR><BR>When compared to peers, such as Amgen with a price-to-earnings ratio of 18.2 and Vertex Pharmaceuticals at 14.0, Lumos Pharma appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of the current price level.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Sep 24

  • NET SALES(HY) At USD 1.21 MM has Grown at 127.34%
  • RAW MATERIAL COST(Y) Fallen by -93.46% (YoY)
  • DEBT-EQUITY RATIO (HY) Lowest at -149.51 %
2

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 38 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

8,985.11%

stock-summary
Debt Equity

-1.50

stock-summary
Return on Equity

-710.54%

stock-summary
Price to Book

7.64

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Sep 2024)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.91%
0%
21.91%
6 Months
70.2%
0%
70.2%
1 Year
48.63%
0%
48.63%
2 Years
19.89%
0%
19.89%
3 Years
-44.14%
0%
-44.14%
4 Years
-75.0%
0%
-75.0%
5 Years
167.9%
0%
167.9%

Lumos Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
20.11%
EBIT Growth (5y)
4.28%
EBIT to Interest (avg)
-31.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.50
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
32.81%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.64
EV to EBIT
-0.83
EV to EBITDA
-0.83
EV to Capital Employed
-12.18
EV to Sales
13.67
PEG Ratio
NA
Dividend Yield
8985.11%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-710.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.23%)

Foreign Institutions

Held by 6 Foreign Institutions (0.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 0.00% vs -100.00% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 9.64% vs -13.70% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-8.90",
          "chgp": "14.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.50",
          "val2": "-8.30",
          "chgp": "9.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,523.40%",
          "val2": "-1,276,000.00%",
          "chgp": "1,26,547.66%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 40.00% vs 650.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -9.32% vs -2.30% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.10",
          "val2": "1.50",
          "chgp": "40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.60",
          "val2": "-32.00",
          "chgp": "-14.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-34.00",
          "val2": "-31.10",
          "chgp": "-9.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,851.80%",
          "val2": "-21,037.40%",
          "chgp": "318.56%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.70
0.00
Operating Profit (PBDIT) excl Other Income
-7.60
-8.90
14.61%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.50
-8.30
9.64%
Operating Profit Margin (Excl OI)
-10,523.40%
-1,276,000.00%
1,26,547.66%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2024 is 0.00% vs -100.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 9.64% vs -13.70% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
2.10
1.50
40.00%
Operating Profit (PBDIT) excl Other Income
-36.60
-32.00
-14.37%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-34.00
-31.10
-9.32%
Operating Profit Margin (Excl OI)
-17,851.80%
-21,037.40%
318.56%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 40.00% vs 650.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -9.32% vs -2.30% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Lumos Pharma, Inc. stock-summary
stock-summary
Lumos Pharma, Inc.
Pharmaceuticals: Major
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
Company Coordinates stock-summary
Company Details
4200 MARATHON BLVD., SUITE 200 , AUSTIN TX : 78756
stock-summary
Tel: 1 512 2152630
stock-summary
https://lumos-pharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."